查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
局部给药市场：2030 年全球预测（按产品、应用、最终用户和地区）
市场调查报告书
商品编码
1787264

局部给药市场：2030 年全球预测（按产品、应用、最终用户和地区）

Topical Drug Delivery Market by Product (Formulation (Semi-solid, Emulsion), Transdermal Patch, Microneedle Patch, Drug-in-adhesive, Matrix Patch), Application (Dermal, Ophthalmic, Nasal, Vaginal, Rectal), End User, Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 435 Pages | 订单完成后即时交付

价格

全球局部给药市场规模预计将从 2025 年的 2,684 亿美元增至 2030 年的 4,090 亿美元，预测期内的复合年增长率为 8.8%。

调查范围
调查年份 2024-2030
基准年 2024
预测期 2025-2030
单元 10亿美元
部分 产品、应用领域、最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

预计该市场的成长将受到以下因素的推动：干眼症局部处方疗法的日益普及、製药公司对创新经皮给药系统研发的日益重视、皮肤感染疾病盛行率的上升以及对非侵入性给药方法的日益偏好。

局部给药市场-IMG1

按产品划分，半固态剂型在 2024 年占据最大的市场占有率。

半固态製剂的高份额归因于其副作用低、患者依从性高、吸收率高、药物释放效率高。这些剂型不会引起脱水，也不会改变皮肤功能，从而推动了市场的成长。

根据应用部位，经皮给药领域在 2024 年占据最大的市场占有率。

经皮给药领域的巨大份额可以归因于市场上新上市产品的不断增加。与经鼻和经眼给药相比，较少的监管要求和较小的刺激性也促进了市场的成长。奈米乳剂经皮给药也适用于治疗牛皮癣和白斑等慢性和自体免疫疾病。

按地区划分，北美在 2024 年占据最大的市场占有率。

该地区的巨大份额归因于皮肤病的高风险、慢性病（如糖尿病）患病率的上升、避孕药具的使用增加、老年人口的增长以及製药公司对创新经皮给药系统的研究和开发的重视。

本报告研究了全球局部给药市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势的资讯。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 主要发现

  • 局部给药市场概述
  • 亚太地区局部给药市场（按产品和国家划分）（2024 年）
  • 局部给药市场：区域构成
  • 局部给药市场：地理成长机会
  • 局部给药市场：已开发市场与新兴市场

第五章市场概述

  • 介绍
  • 市场动态
    • 驱动程式
    • 抑制因素
    • 机会
    • 任务
  • 产业趋势
    • 经皮给药系统的进展
    • 微针贴片技术的出现
  • 技术分析
    • 主要技术
    • 互补技术
    • 邻近技术
  • 波特五力分析
  • 监管格局
    • 监管分析
    • 监管机构、政府机构和其他组织
  • 专利分析
    • 局部药物传递相关专利出版品的趋势
    • 讨论：管辖权和主要申请人分析
  • 贸易分析
  • 定价分析
    • 各产品平均售价趋势（2022-2024）
    • 主要企业药膏平均销售价格（2024年）
    • 主要企业凝胶平均售价（2024年）
    • 各地区平均销售价格
    • 各地区半固态剂型平均售价（2024年）
  • 报销分析
  • 大型会议和活动（2025-2026年）
  • 主要相关利益者和采购标准
  • 未满足的需求/最终用户期望
  • 人工智慧对局部给药市场的影响
  • 管道分析
  • 生态系市场图
  • 价值链分析
  • 投资金筹措场景
  • 川普关税局部药物输送市场的影响
    • 介绍
    • 主要关税税率
    • 价格影响分析
    • 对各地区产生重大影响
    • 对终端产业的影响

第六章局部给药市场（依产品）

  • 介绍
  • 半固态製剂
    • 软膏
    • 奶油
    • 洗剂
    • 凝胶
    • 贴上
  • 液体製剂
    • 暂停
    • 乳剂
    • 液体
  • 固态剂型
    • 粉末
    • 栓剂
    • 电影
  • 经皮
    • 经皮吸收贴片
    • 经皮凝胶
    • 经皮喷雾
  • 其他产品

第七章局部给药市场（依应用部位）

  • 介绍
  • 皮肤药物输送
  • 眼部药物输送
  • 阴道给药
  • 直肠给药
  • 鼻腔给药

第八章局部给药市场（依最终用户划分）

  • 介绍
  • 居家照护环境
  • 医院和诊所
  • 门诊手术中心
  • 烧伤护理中心
  • 其他最终用户

第九章局部给药市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 其他欧洲国家
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 越南
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲
    • 中东和非洲的宏观经济展望
    • 海湾合作委员会国家
    • 其他中东和非洲地区

第十章 竞争格局

  • 概述
  • 主要参与企业的策略/优势
  • 收益分析（2020-2024）
  • 市场占有率分析
  • 企业评估矩阵：主要企业（2024年）
  • 公司评估矩阵：Start-Ups/中小企业（2024 年）
  • 品牌/产品比较
  • 主要企业研发支出
  • 公司估值及财务指标
  • 竞争场景

第十一章：公司简介

  • 主要企业
    • JOHNSON & JOHNSON SERVICES, INC.
    • GALDERMA
    • BAYER AG
    • NOVARTIS AG
    • ABBVIE INC.
    • GLENMARK PHARMACEUTICALS LIMITED
    • GSK PLC.
    • BAUSCH HEALTH COMPANIES INC.
    • HISAMITSU PHARMACEUTICAL CO., INC.
    • CIPLA
    • VIATRIS INC.
    • ORGANON GROUP OF COMPANIES
    • PFIZER, INC.
    • CRESCITA THERAPEUTICS INC.
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • SOLVENTUM
    • LUYE PHARMA GROUP
    • LEAD CHEMICAL CO., LTD.
    • PURDUE PHARMA LP
    • LAVIPHARM
  • 其他公司
    • CMP PHARMA, INC.
    • ENCORE DERMATOLOGY, INC.
    • RUSAN PHARMA LTD.
    • ADHEXPHARMA

第十二章 附录

Product Code: PH 7545

The global topical drug delivery market is expected to reach USD 409.0 billion by 2030 from USD 268.4 billion in 2025, at a CAGR of 8.8% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct, Site of Application, and End User
Regions coveredNorth America, Europe, APAC, LATAM, MEA

The growth of this market can largely be attributed to the uptake of topical prescription therapy for dry eye diseases, the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems, the increasing prevalence of skin infections, and the rising preference for non-invasive drug delivery methods.

Topical Drug Delivery Market - IMG1

By product, the semi-solid formulations segment accounted for the largest market share in 2024.

By product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. The large share of the semi-solid formulations segment is attributed to enhanced patient adherence with limited side effects, high absorption, and efficient provision of drug release. These dosage forms are non-dehydrating and do not modify skin functioning, fueling market growth.

By site of application, the dermal drug delivery segment accounted for the largest market share in 2024.

By site of application, the market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. The large share of the dermal drug delivery segment can be attributed to the increasing product launches in the market. Fewer regulatory requirements and lower irritation than nasal or ophthalmic drug delivery also contribute to market growth. Dermal drug delivery through nanoemulsions is also suitable for chronic and autoimmune diseases, such as psoriasis and vitiligo.

By region, North America accounted for the largest market share in 2024.

By region, North America accounted for the largest share of the market in 2024. The large share of this region is attributed to the high risk of skin disorders, the rising prevalence of chronic diseases (such as diabetes), increasing use of contraceptives, the increasing geriatric population, and the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
  • By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
  • By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

  • By Company Type: Hospitals & Clinics (60%), Ambulatory Surgery Centers (25%), and Home Care Settings (15%)
  • By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%)
  • By Region: North America (40%), Europe (25%), the Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Key players in the Topical Drug Delivery Market

The prominent players in the topical drug delivery market are Johnson & Johnson Private Limited (US), Galderma (Switzerland), Bayer AG (Germany), Novartis International AG (Switzerland), AbbVie Inc. (US), GSK Plc. (UK), Bausch Health Companies Inc. (Canada), Glenmark Pharmaceuticals Ltd. (India), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Organon group of companies (US), Solventum (US), Crescita Therapeutics Inc. (Canada), Luye Pharma Group (China), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Rusan Pharma Ltd. (India), and AdhexPharma (France).

Research Coverage:

The report analyzes the topical drug delivery market. It aims to estimate the market size and future growth potential of this market based on various segments such as product, site of application, end user, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the following strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the topical drug delivery market. The report analyzes this market by product, site of application, and end users.
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the topical drug delivery market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various topical drug delivery products across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the topical drug delivery market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the topical drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS & REGIONS COVERED
    • 1.2.3 YEARS CONSIDERED
    • 1.2.4 CURRENCY CONSIDERED
  • 1.3 MARKET STAKEHOLDERS
  • 1.4 LIMITATIONS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH METHODOLOGY DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Key industry insights
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 APPROACH 1: REVENUE SHARE ANALYSIS
    • 2.3.2 APPROACH 2: PHARMACEUTICAL SALES ANALYSIS
    • 2.3.3 APPROACH 3: TOP-DOWN APPROACH
    • 2.3.4 APPROACH 4: BOTTOM-UP APPROACH
    • 2.3.5 APPROACH 4: PRIMARY INTERVIEWS
    • 2.3.6 APPROACH 5: DEMAND-SIDE APPROACH
    • 2.3.7 APPROACH 6: VOLUME DATA ANALYSIS
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
    • 2.6.1 GROWTH RATE ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
  • 2.8 LIMITATIONS
    • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT & COUNTRY (2024)
  • 4.3 TOPICAL DRUG DELIVERY MARKET: REGIONAL MIX
  • 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of skin disorders
      • 5.2.1.2 High incidence of burn injuries
      • 5.2.1.3 Growing emphasis on patient convenience
      • 5.2.1.4 Increasing investments in pharmaceutical R&D
      • 5.2.1.5 Rising incidence of chronic diseases
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adverse skin reactions & allergies
      • 5.2.2.2 Drug failure & recalls of TDD systems
      • 5.2.2.3 High development costs of topical drug delivery products
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing preference for self-administration and home care
      • 5.2.3.2 High growth potential of emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical barriers related to skin irritation & permeability
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS
    • 5.3.2 EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Nanocarrier-based delivery systems
      • 5.4.1.2 Microemulsions & nanoemulsion
      • 5.4.1.3 Thermosensitive & pH-sensitive hydrogels & hydrocolloids
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Microneedle-enhanced delivery
      • 5.4.2.2 AI-assisted formulations & prediction models
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Wearable sensor-integrated topical patches
      • 5.4.3.2 3D testing skin models
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 REGULATORY ANALYSIS
    • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 PATENT ANALYSIS
    • 5.7.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
    • 5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
  • 5.8 TRADE ANALYSIS
    • 5.8.1 TRADE DATA FOR HS CODE 300490
      • 5.8.1.1 Import data for HS Code 300490
      • 5.8.1.2 Export data for HS Code 300490
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
    • 5.9.2 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
    • 5.9.3 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
    • 5.9.4 AVERAGE SELLING PRICE, BY REGION
    • 5.9.5 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
      • 5.9.5.1 Average selling price trend of ointments, by region, 2022-2024
      • 5.9.5.2 Average selling price trend of creams, by region, 2022-2024
      • 5.9.5.3 Average selling price trend of gels, by region, 2022-2024
  • 5.10 REIMBURSEMENT ANALYSIS
  • 5.11 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.12.2 BUYING CRITERIA
  • 5.13 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.14 IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET
    • 5.14.1 AI-USE CASES
  • 5.15 PIPELINE ANALYSIS
  • 5.16 ECOSYSTEM MARKET MAP
  • 5.17 VALUE CHAIN ANALYSIS
  • 5.18 INVESTMENT & FUNDING SCENARIO
  • 5.19 TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET
    • 5.19.1 INTRODUCTION
    • 5.19.2 KEY TARIFF RATES
    • 5.19.3 PRICE IMPACT ANALYSIS
    • 5.19.4 KEY IMPACT ON VARIOUS REGIONS
    • 5.19.5 END-USE INDUSTRY IMPACT

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 SEMI-SOLID FORMULATIONS
    • 6.2.1 OINTMENTS
      • 6.2.1.1 Wide applications in analgesic indications to drive market
    • 6.2.2 CREAMS
      • 6.2.2.1 High absorption capabilities to boost demand
    • 6.2.3 LOTIONS
      • 6.2.3.1 Convenient application to fuel uptake
    • 6.2.4 GELS
      • 6.2.4.1 Enhanced patient compliance and aesthetic appeal to drive market
    • 6.2.5 PASTES
      • 6.2.5.1 Prevention of skin irritation to fuel uptake
  • 6.3 LIQUID FORMULATIONS
    • 6.3.1 SUSPENSIONS
      • 6.3.1.1 Higher rate of bioavailability and controlled onset of action to drive market
    • 6.3.2 EMULSIONS
      • 6.3.2.1 Versatile carriers for enhanced drug delivery to fuel uptake
    • 6.3.3 SOLUTIONS
      • 6.3.3.1 Uniform & rapid drug delivery to boost demand
  • 6.4 SOLID FORMULATIONS
    • 6.4.1 POWDERS
      • 6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel market
    • 6.4.2 SUPPOSITORIES
      • 6.4.2.1 Ability to ensure drug compatibility to fuel market
    • 6.4.3 FILM
      • 6.4.3.1 Next-generation advancements to boost demand
  • 6.5 TRANSDERMAL PRODUCTS
    • 6.5.1 TRANSDERMAL PATCHES
      • 6.5.1.1 Drug-in-adhesive patches
        • 6.5.1.1.1 Enhanced drug release to fuel uptake
      • 6.5.1.2 Matrix patches
        • 6.5.1.2.1 Rising technological advancements to boost demand
      • 6.5.1.3 Reservoir membrane patches
        • 6.5.1.3.1 Prolonged drug delivery to fuel market
      • 6.5.1.4 Microneedle patches
        • 6.5.1.4.1 Ability to deliver APIs to support market growth
      • 6.5.1.5 Iontophoresis patches
        • 6.5.1.5.1 Low molecular weight patches to support market growth
      • 6.5.1.6 Vapor patches
        • 6.5.1.6.1 Ability to release essential oils to support market growth
    • 6.5.2 TRANSDERMAL GELS
      • 6.5.2.1 Rapid release of drugs to fuel uptake
    • 6.5.3 TRANSDERMAL SPRAYS
      • 6.5.3.1 Targeted approach to boost demand
  • 6.6 OTHER PRODUCTS

7 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 DERMAL DRUG DELIVERY
    • 7.2.1 STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET
  • 7.3 OPHTHALMIC DRUG DELIVERY
    • 7.3.1 FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND
  • 7.4 VAGINAL DRUG DELIVERY
    • 7.4.1 LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET
  • 7.5 RECTAL DRUG DELIVERY
    • 7.5.1 COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE
  • 7.6 NASAL DRUG DELIVERY
    • 7.6.1 QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE

8 TOPICAL DRUG DELIVERY MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOME CARE SETTINGS
    • 8.2.1 HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET
  • 8.3 HOSPITALS & CLINICS
    • 8.3.1 ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET
  • 8.4 AMBULATORY SURGERY CENTERS
    • 8.4.1 UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND
  • 8.5 BURN CARE CENTERS
    • 8.5.1 HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH
  • 8.6 OTHER END USERS

9 TOPICAL DRUG DELIVERY MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 9.2.2 US
      • 9.2.2.1 Rising prevalence of skin diseases to drive market
    • 9.2.3 CANADA
      • 9.2.3.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
  • 9.3 EUROPE
    • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 9.3.2 GERMANY
      • 9.3.2.1 Growing focus of R&D for pharmaceutical API development to boost demand
    • 9.3.3 UK
      • 9.3.3.1 Rising demand for painless treatment alternatives to fuel market
    • 9.3.4 FRANCE
      • 9.3.4.1 Rising incidence of diabetes and subsequent increase in skin lesions to drive market
    • 9.3.5 ITALY
      • 9.3.5.1 Rising demand for transdermal patches to propel market
    • 9.3.6 SPAIN
      • 9.3.6.1 Expanding research hub to fuel market
    • 9.3.7 NETHERLANDS
      • 9.3.7.1 Public awareness initiatives for preventive care to fuel uptake
    • 9.3.8 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 9.4.2 CHINA
      • 9.4.2.1 Rising cases of communicable diseases to drive market
    • 9.4.3 JAPAN
      • 9.4.3.1 Increasing number of product approvals to drive market
    • 9.4.4 INDIA
      • 9.4.4.1 Growing focus on adoption of non-invasive drug delivery methods to drive market
    • 9.4.5 AUSTRALIA
      • 9.4.5.1 Increasing number of smokers to fuel uptake
    • 9.4.6 SOUTH KOREA
      • 9.4.6.1 Favorable government focus on expanding clinical trials to boost demand
    • 9.4.7 THAILAND
      • 9.4.7.1 Regulatory reforms and supportive healthcare initiatives to support market growth
    • 9.4.8 VIETNAM
      • 9.4.8.1 Increasing investments and regulatory reforms to fuel uptake
    • 9.4.9 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 9.5.2 BRAZIL
      • 9.5.2.1 High prevalence of diabetes to propel market growth
    • 9.5.3 MEXICO
      • 9.5.3.1 Increasing prevalence of glaucoma to drive market
    • 9.5.4 REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 9.6.2 GCC COUNTRIES
      • 9.6.2.1 Kingdom of Saudi Arabia (KSA)
        • 9.6.2.1.1 Expanding healthcare infrastructure to boost demand
      • 9.6.2.2 United Arab Emirates (UAE)
        • 9.6.2.2.1 Increasing prevalence of diabetes to fuel uptake
      • 9.6.2.3 Other GCC Countries
    • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
  • 10.3 REVENUE ANALYSIS, 2020-2024
  • 10.4 MARKET SHARE ANALYSIS
    • 10.4.1 RANKING OF KEY MARKET PLAYERS
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 10.5.5.1 Company footprint
      • 10.5.5.2 Region footprint
      • 10.5.5.3 Product footprint
      • 10.5.5.4 Site of application footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 RESPONSIVE COMPANIES
    • 10.6.3 DYNAMIC COMPANIES
    • 10.6.4 STARTING BLOCKS
    • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 10.6.5.1 Detailed list of key startups/SME players
      • 10.6.5.2 Competitive benchmarking of key emerging players/startups
  • 10.7 BRAND/PRODUCT COMPARISON
    • 10.7.1 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 10.8 R&D EXPENDITURE OF KEY PLAYERS
    • 10.8.1 R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
  • 10.9 COMPANY VALUATION & FINANCIAL METRICS
    • 10.9.1 FINANCIAL METRICS
    • 10.9.2 COMPANY VALUATION
  • 10.10 COMPETITIVE SCENARIO
    • 10.10.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
    • 10.10.2 DEALS
    • 10.10.3 EXPANSIONS
    • 10.10.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
    • 11.1.1 JOHNSON & JOHNSON SERVICES, INC.
      • 11.1.1.1 Business overview
      • 11.1.1.2 Products offered
      • 11.1.1.3 Recent developments
        • 11.1.1.3.1 Product approvals
        • 11.1.1.3.2 Deals
      • 11.1.1.4 MnM view
        • 11.1.1.4.1 Key strengths
        • 11.1.1.4.2 Strategic choices
        • 11.1.1.4.3 Weaknesses & competitive threats
    • 11.1.2 GALDERMA
      • 11.1.2.1 Business overview
      • 11.1.2.2 Products offered
      • 11.1.2.3 Recent developments
        • 11.1.2.3.1 Product launches & approvals
        • 11.1.2.3.2 Deals
        • 11.1.2.3.3 Expansions
      • 11.1.2.4 MnM view
        • 11.1.2.4.1 Key strengths
        • 11.1.2.4.2 Strategic choices
        • 11.1.2.4.3 Weaknesses & competitive threats
    • 11.1.3 BAYER AG
      • 11.1.3.1 Business overview
      • 11.1.3.2 Products offered
      • 11.1.3.3 Recent developments
        • 11.1.3.3.1 Product launches & approvals
        • 11.1.3.3.2 Deals
      • 11.1.3.4 MnM view
        • 11.1.3.4.1 Key strengths
        • 11.1.3.4.2 Strategic choices
        • 11.1.3.4.3 Weaknesses & competitive threats
    • 11.1.4 NOVARTIS AG
      • 11.1.4.1 Business overview
      • 11.1.4.2 Products offered
      • 11.1.4.3 Recent developments
        • 11.1.4.3.1 Deals
        • 11.1.4.3.2 Other developments
      • 11.1.4.4 MnM view
        • 11.1.4.4.1 Key strengths
        • 11.1.4.4.2 Strategic choices
        • 11.1.4.4.3 Weaknesses & competitive threats
    • 11.1.5 ABBVIE INC.
      • 11.1.5.1 Business overview
      • 11.1.5.2 Products offered
      • 11.1.5.3 Recent developments
        • 11.1.5.3.1 Product launches
        • 11.1.5.3.2 Expansions
        • 11.1.5.3.3 Other developments
      • 11.1.5.4 MnM view
        • 11.1.5.4.1 Key strengths
        • 11.1.5.4.2 Strategic choices
        • 11.1.5.4.3 Weaknesses & competitive threats
    • 11.1.6 GLENMARK PHARMACEUTICALS LIMITED
      • 11.1.6.1 Business overview
      • 11.1.6.2 Products offered
      • 11.1.6.3 Recent developments
        • 11.1.6.3.1 Product approvals
        • 11.1.6.3.2 Deals
    • 11.1.7 GSK PLC.
      • 11.1.7.1 Business overview
      • 11.1.7.2 Products offered
      • 11.1.7.3 Recent developments
        • 11.1.7.3.1 Deals
        • 11.1.7.3.2 Other developments
    • 11.1.8 BAUSCH HEALTH COMPANIES INC.
      • 11.1.8.1 Business overview
      • 11.1.8.2 Products offered
      • 11.1.8.3 Recent developments
        • 11.1.8.3.1 Product launches & approvals
        • 11.1.8.3.2 Deals
    • 11.1.9 HISAMITSU PHARMACEUTICAL CO., INC.
      • 11.1.9.1 Business overview
      • 11.1.9.2 Products offered
      • 11.1.9.3 Recent developments
        • 11.1.9.3.1 Product launches, enhancements, and approvals
        • 11.1.9.3.2 Deals
        • 11.1.9.3.3 Expansions
    • 11.1.10 CIPLA
      • 11.1.10.1 Business overview
      • 11.1.10.2 Products offered
      • 11.1.10.3 Recent developments
        • 11.1.10.3.1 Deals
    • 11.1.11 VIATRIS INC.
      • 11.1.11.1 Business overview
      • 11.1.11.2 Products offered
      • 11.1.11.3 Recent developments
        • 11.1.11.3.1 Product launches & approvals
        • 11.1.11.3.2 Deals
        • 11.1.11.3.3 Other developments
    • 11.1.12 ORGANON GROUP OF COMPANIES
      • 11.1.12.1 Business overview
      • 11.1.12.2 Products offered
      • 11.1.12.3 Recent developments
        • 11.1.12.3.1 Product approvals
        • 11.1.12.3.2 Deals
    • 11.1.13 PFIZER, INC.
      • 11.1.13.1 Business overview
      • 11.1.13.2 Products offered
      • 11.1.13.3 Recent developments
        • 11.1.13.3.1 Product approvals
        • 11.1.13.3.2 Deals
    • 11.1.14 CRESCITA THERAPEUTICS INC.
      • 11.1.14.1 Business overview
      • 11.1.14.2 Products offered
      • 11.1.14.3 Recent developments
        • 11.1.14.3.1 Deals
        • 11.1.14.3.2 Other developments
    • 11.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 11.1.15.1 Business overview
      • 11.1.15.2 Products offered
      • 11.1.15.3 Recent developments
        • 11.1.15.3.1 Deals
        • 11.1.15.3.2 Expansions
    • 11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 11.1.16.1 Business overview
      • 11.1.16.2 Products offered
      • 11.1.16.3 Recent developments
        • 11.1.16.3.1 Deals
    • 11.1.17 SOLVENTUM
      • 11.1.17.1 Business overview
      • 11.1.17.2 Products offered
      • 11.1.17.3 Recent developments
        • 11.1.17.3.1 Deals
    • 11.1.18 LUYE PHARMA GROUP
      • 11.1.18.1 Business overview
      • 11.1.18.2 Products offered
      • 11.1.18.3 Recent developments
        • 11.1.18.3.1 Product approvals
        • 11.1.18.3.2 Deals
    • 11.1.19 LEAD CHEMICAL CO., LTD.
      • 11.1.19.1 Business overview
      • 11.1.19.2 Products offered
    • 11.1.20 PURDUE PHARMA L.P.
      • 11.1.20.1 Business overview
      • 11.1.20.2 Products offered
    • 11.1.21 LAVIPHARM
      • 11.1.21.1 Business overview
      • 11.1.21.2 Products offered
  • 11.2 OTHER PLAYERS
    • 11.2.1 CMP PHARMA, INC.
    • 11.2.2 ENCORE DERMATOLOGY, INC.
    • 11.2.3 RUSAN PHARMA LTD.
    • 11.2.4 ADHEXPHARMA

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS

List of Tables

  • TABLE 1 STANDARD CURRENCY CONVERSION RATES (USD)
  • TABLE 2 TOPICAL DRUG DELIVERY MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 KEY DEVELOPMENTS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS
  • TABLE 4 TOPICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 5 REGULATORY ADHERENCE FOR TOPICAL DRUG DELIVERY PRODUCTS, BY REGION
  • TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 TOPICAL DRUG DELIVERY MARKET: MAJOR PATENTS
  • TABLE 13 IMPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021-2024 (USD THOUSANDS)
  • TABLE 14 EXPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021-2024 (USD THOUSANDS)
  • TABLE 15 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022-2024
  • TABLE 16 AVERAGE SELLING PRICE TREND OF OINTMENTS, BY REGION, 2022-2024
  • TABLE 17 AVERAGE SELLING PRICE TREND FOR CREAMS, BY REGION, 2022-2024
  • TABLE 18 AVERAGE SELLING PRICE TREND OF GELS, BY REGION, 2022-2024
  • TABLE 19 TOPICAL DRUG DELIVERY MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS (%)
  • TABLE 21 KEY BUYING CRITERIA, BY END USER
  • TABLE 22 TOPICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE (2024)
  • TABLE 23 TOPICAL DRUG DELIVERY PRODUCTS PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 25 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR TOPICAL DRUG DELIVERY PRODUCTS
  • TABLE 26 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
  • TABLE 27 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
  • TABLE 28 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
  • TABLE 29 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
  • TABLE 30 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 31 KEY PLAYERS OFFERING SEMI-SOLID FORMULATIONS
  • TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 33 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 34 KEY PLAYERS OFFERING OINTMENTS
  • TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 37 KEY PLAYERS OFFERING CREAMS
  • TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 40 KEY PLAYERS OFFERING LOTIONS
  • TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 42 KEY PLAYERS OFFERING GELS
  • TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 44 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 45 KEY PLAYERS OFFERING PASTES
  • TABLE 46 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 47 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 48 KEY PLAYERS OFFERING LIQUID FORMULATIONS
  • TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 50 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 51 KEY PLAYERS OFFERING SUSPENSIONS
  • TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 53 KEY PLAYERS OFFERING EMULSIONS
  • TABLE 54 TOPICAL DRUG DELIVERY MARKET FOR EMULSIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 55 KEY PLAYERS OFFERING SOLUTIONS
  • TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 59 KEY PLAYERS OFFERING SOLID FORMULATIONS
  • TABLE 60 KEY PLAYERS OFFERING POWDERS
  • TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 62 KEY PLAYERS OFFERING SUPPOSITORIES
  • TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 64 KEY PLAYERS OFFERING FILM
  • TABLE 65 TOPICAL DRUG DELIVERY MARKET FOR FILM, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 66 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 67 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 68 KEY PLAYERS OFFERING TRANSDERMAL PRODUCTS
  • TABLE 69 KEY PLAYERS OFFERING TRANSDERMAL PATCHES
  • TABLE 70 TRANSDERMAL PATCHES MARKET, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 71 TRANSDERMAL PATCHES MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 72 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 73 KEY PLAYERS OFFERING DRUG-IN-ADHESIVE PATCHES
  • TABLE 74 TRANSDERMAL DRUG-IN-ADHESIVE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 75 KEY PLAYERS OFFERING MATRIX PATCHES
  • TABLE 76 TRANSDERMAL MATRIX PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 77 KEY PLAYERS OFFERING RESERVOIR MEMBRANE PATCHES
  • TABLE 78 TRANSDERMAL RESERVOIR MEMBRANE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 79 KEY PLAYERS OFFERING MICRONEEDLE PATCHES
  • TABLE 80 TRANSDERMAL MICRONEEDLE PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 81 KEY PLAYERS OFFERING IONTOPHORESIS PATCHES
  • TABLE 82 TRANSDERMAL IONTOPHORESIS PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 83 KEY PLAYERS OFFERING VAPOR PATCHES
  • TABLE 84 TRANSDERMAL VAPOR PATCHES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 85 KEY PLAYERS OFFERING TRANSDERMAL GELS
  • TABLE 86 TRANSDERMAL GELS MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 87 TRANSDERMAL GELS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 88 KEY PLAYERS OFFERING TRANSDERMAL SPRAYS
  • TABLE 89 TRANSDERMAL SPRAYS MARKET, BY REGION, 2023-2030 (TEN THOUSAND UNITS)
  • TABLE 90 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 91 TOPICAL DRUG DELIVERY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 92 KEY PLAYERS OFFERING OTHER PRODUCTS
  • TABLE 93 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 94 KEY PLAYERS OFFERING DERMAL DRUG DELIVERY PRODUCTS
  • TABLE 95 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 96 KEY PLAYERS OFFERING OPHTHALMIC DRUG DELIVERY PRODUCTS
  • TABLE 97 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 98 KEY PLAYERS OFFERING VAGINAL DRUG DELIVERY PRODUCTS
  • TABLE 99 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 100 KEY PLAYERS OFFERING RECTAL DRUG DELIVERY PRODUCTS
  • TABLE 101 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 102 KEY PLAYERS OFFERING NASAL DRUG DELIVERY PRODUCTS
  • TABLE 103 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 104 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 105 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 106 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 107 TOPICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 108 TOPICAL DRUG DELIVERY MARKET FOR BURN CARE CENTERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 109 TOPICAL DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 110 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 111 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 112 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 113 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 114 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 115 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 116 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 117 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 118 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 119 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 120 US: KEY MACROINDICATORS
  • TABLE 121 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 122 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 123 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 124 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 125 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 126 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 127 US: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 128 US: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 129 CANADA: KEY MACROINDICATORS
  • TABLE 130 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 131 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 132 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 133 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 134 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 135 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 136 CANADA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 137 CANADA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 138 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 139 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 140 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 141 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 142 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 143 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 144 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 145 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 146 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 147 GERMANY: KEY MACROINDICATORS
  • TABLE 148 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 149 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 150 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 151 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 152 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 153 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 154 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 155 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 156 UK: KEY MACROINDICATORS
  • TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 158 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 159 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 160 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 161 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 162 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 163 UK: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 164 UK: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 165 FRANCE: KEY MACROINDICATORS
  • TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 172 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 173 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 174 ITALY: KEY MACROINDICATORS
  • TABLE 175 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 176 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 177 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 178 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 179 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 180 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 181 ITALY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 182 ITALY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 183 SPAIN: KEY MACROINDICATORS
  • TABLE 184 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 185 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 186 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 187 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 188 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 189 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 190 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 191 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 192 NETHERLANDS: KEY MACROINDICATORS
  • TABLE 193 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 194 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 195 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 196 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 197 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 198 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 199 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 200 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 201 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 202 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 203 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 204 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 205 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 206 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 207 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 208 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 209 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 210 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 211 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 212 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 213 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 214 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 215 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 216 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 217 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 218 CHINA: MACROECONOMIC INDICATORS
  • TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 227 JAPAN: MACROECONOMIC INDICATORS
  • TABLE 228 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 229 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 230 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 231 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 232 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 233 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 234 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 235 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 236 INDIA: MACROECONOMIC INDICATORS
  • TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 245 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 246 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 247 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 248 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 249 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 250 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 251 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 252 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 253 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 254 SOUTH KOREA: MACROECONOMIC INDICATORS
  • TABLE 255 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 256 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 257 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 258 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 259 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 260 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 261 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 262 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 263 THAILAND: MACROECONOMIC INDICATORS
  • TABLE 264 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 265 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 266 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 267 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 268 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 269 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 270 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 271 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 272 VIETNAM: MACROECONOMIC INDICATORS
  • TABLE 273 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 274 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 275 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 276 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 277 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 278 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 279 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 280 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 281 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 282 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 283 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 284 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 285 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 286 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 287 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 288 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 289 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 290 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 291 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 292 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 293 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 294 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 295 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 296 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 297 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 298 BRAZIL: MACROECONOMIC INDICATORS
  • TABLE 299 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 300 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 301 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 302 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 303 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 304 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 305 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 306 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 307 MEXICO: MACROECONOMIC INDICATORS
  • TABLE 308 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 309 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 310 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 311 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 312 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 313 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 314 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 315 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 316 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 317 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 318 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 319 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 320 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 321 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 322 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 323 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 324 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
  • TABLE 325 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 326 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 327 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 328 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 329 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 330 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 331 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 332 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 333 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
  • TABLE 334 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 335 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 336 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 337 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 338 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 339 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 340 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 341 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 342 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
  • TABLE 343 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 344 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 345 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 346 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 347 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 348 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 349 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 350 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 351 UNITED ARAB EMIRATES: KEY MACROINDICATORS
  • TABLE 352 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 353 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 354 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 355 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 356 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 357 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 358 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 359 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 360 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 361 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 362 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 363 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 364 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 365 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 366 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 367 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 368 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
  • TABLE 369 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 370 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 371 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 372 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 373 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 374 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023-2030 (USD BILLION)
  • TABLE 375 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
  • TABLE 376 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
  • TABLE 377 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
  • TABLE 378 TOPICAL DRUG DELIVERY MARKET: REGION FOOTPRINT
  • TABLE 379 TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE FOOTPRINT
  • TABLE 380 TOPICAL DRUG DELIVERY MARKET: SITE OF APPLICATION FOOTPRINT
  • TABLE 381 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 382 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 383 TOPICAL DRUG DELIVERY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 384 TOPICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 385 TOPICAL DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 386 TOPICAL DRUG DELIVERY MARKET: OTHERS, JANUARY 2022-JUNE 2025
  • TABLE 387 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 388 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 389 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 390 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 391 GALDERMA: COMPANY OVERVIEW
  • TABLE 392 GALDERMA: PRODUCTS OFFERED
  • TABLE 393 GALDERMA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 394 GALDERMA: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 395 GALDERMA: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 396 BAYER AG: COMPANY OVERVIEW
  • TABLE 397 BAYER AG: PRODUCTS OFFERED
  • TABLE 398 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 399 BAYER AG: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 400 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 401 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 402 NOVARTIS AG: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 403 NOVARTIS AG: OTHERS, JANUARY 2022-JUNE 2025
  • TABLE 404 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 405 ABBVIE, INC.: PRODUCTS OFFERED
  • TABLE 406 ABBVIE INC.: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
  • TABLE 407 ABBVIE, INC.: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 408 ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 409 GLENMARK PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
  • TABLE 410 GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
  • TABLE 411 GLENMARK PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 412 GLENMARK PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 413 GSK PLC.: COMPANY OVERVIEW
  • TABLE 414 GSK PLC.: PRODUCTS OFFERED
  • TABLE 415 GSK PLC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 416 GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 417 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
  • TABLE 418 BAUSCH HEALTH COMPANIES, INC.: PRODUCTS OFFERED
  • TABLE 419 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 420 BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 421 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY OVERVIEW
  • TABLE 422 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCTS OFFERED
  • TABLE 423 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 424 HISAMITSU PHARMACEUTICAL CO., INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 425 HISAMITSU PHARMACEUTICAL CO., INC.: EXPANSIONS, JANUARY 2022-JUNE 2025
  • TABLE 426 CIPLA: COMPANY OVERVIEW
  • TABLE 427 CIPLA: PRODUCTS OFFERED
  • TABLE 428 CIPLA: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 429 VIATRIS INC.: COMPANY OVERVIEW
  • TABLE 430 VIATRIS INC.: PRODUCTS OFFERED
  • TABLE 431 VIATRIS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 432 VIATRIS INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 433 VIATRIS INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 434 ORGANON GROUP OF COMPANIES: COMPANY OVERVIEW
  • TABLE 435 ORGANON GROUP OF COMPANIES: PRODUCTS OFFERED
  • TABLE 436 ORGANON GROUP OF COMPANIES: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 437 ORGANON GROUP OF COMPANIES: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 438 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 439 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 440 PFIZER, INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 441 PFIZER, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 442 CRESCITA THERAPEUTICS INC.: COMPANY OVERVIEW
  • TABLE 443 CRESCITA THERAPEUTICS INC.: PRODUCTS OFFERED
  • TABLE 444 CRESCITA THERAPEUTICS INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 445 CRESCITA THERAPEUTICS INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 446 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 447 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
  • TABLE 448 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 449 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 450 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 451 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 452 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 453 SOLVENTUM: COMPANY OVERVIEW
  • TABLE 454 SOLVENTUM: PRODUCTS OFFERED
  • TABLE 455 SOLVENTUM DEALS, JANUARY 2022-JUNE 2025
  • TABLE 456 LUYE PHARMA GROUP: COMPANY OVERVIEW
  • TABLE 457 LUYE PHARMA GROUP: PRODUCTS OFFERED
  • TABLE 458 LUYE PHARMA GROUP: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 459 LUYE PHARMA GROUP: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 460 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 461 PURDUE PHARMA L.P.: COMPANY OVERVIEW
  • TABLE 462 PURDUE PHARMA L.P.: PRODUCTS OFFERED
  • TABLE 463 LAVIPHARM: COMPANY OVERVIEW
  • TABLE 464 LAVIPHARM: PRODUCTS OFFERED
  • TABLE 465 CMP PHARMA, INC.: COMPANY OVERVIEW
  • TABLE 466 ENCORE DERMATOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 467 RUSAN PHARMA LTD.: COMPANY OVERVIEW
  • TABLE 468 ADHEXPHARMA: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 TOPICAL DRUG DELIVERY MARKET & REGIONAL SEGMENTATION
  • FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
  • FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
  • FIGURE 8 TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
  • FIGURE 9 REVENUE ANALYSIS OF TOP FIVE COMPANIES: TOPICAL DRUG DELIVERY MARKET (2024)
  • FIGURE 10 PHARMACEUTICAL SALES APPROACH
  • FIGURE 11 TOP-DOWN APPROACH
  • FIGURE 12 BOTTOM-UP APPROACH
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2025-2030): IMPACT ON MARKET GROWTH & CAGR)
  • FIGURE 14 CAGR PROJECTIONS
  • FIGURE 15 DATA TRIANGULATION METHODOLOGY
  • FIGURE 16 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
  • FIGURE 17 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2025 VS. 2030 (USD BILLION)
  • FIGURE 18 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
  • FIGURE 19 GEOGRAPHIC SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET
  • FIGURE 20 INCREASING PREVALENCE OF SKIN DISORDERS AND RISING INCIDENCE OF BURN INJURIES TO PROPEL MARKET
  • FIGURE 21 SEMI-SOLID FORMULATIONS SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 22 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 23 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 25 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 BIOPHARMACEUTICAL R&D SPENDING (2020-2026)
  • FIGURE 27 TOP PHARMA R&D INVESTMENTS: LEADING COMPANY INVESTMENTS, 2023
  • FIGURE 28 TOPICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 TOPICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2014-JUNE 2025)
  • FIGURE 30 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2014-JUNE 2025)
  • FIGURE 31 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
  • FIGURE 32 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
  • FIGURE 33 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS
  • FIGURE 35 KEY BUYING CRITERIA FOR TOPICAL DRUG DELIVERY PRODUCTS, BY TOP THREE END USERS
  • FIGURE 36 AI-USE CASES
  • FIGURE 37 TOPICAL DRUG DELIVERY MARKET: ECOSYSTEM MAP
  • FIGURE 38 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 39 TOPICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO, 2020-2024
  • FIGURE 40 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 41 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 42 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2022-2024
  • FIGURE 44 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 45 RANKING OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2024
  • FIGURE 46 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 47 TOPICAL DRUG DELIVERY MARKET: COMPANY FOOTPRINT
  • FIGURE 48 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 49 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 50 R&D EXPENDITURE OF KEY PLAYERS, 2022-2024
  • FIGURE 51 EV/EBITDA OF KEY VENDORS
  • FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 54 GALDERMA: COMPANY SNAPSHOT (2024)
  • FIGURE 55 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 57 ABBVIE, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 59 GSK PLC.: COMPANY SNAPSHOT (2024)
  • FIGURE 60 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 61 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 62 CIPLA: COMPANY SNAPSHOT (2024)
  • FIGURE 63 VIATRIS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 64 ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024)
  • FIGURE 65 PFIZER, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 66 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 67 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
  • FIGURE 68 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 69 SOLVENTUM: COMPANY SNAPSHOT (2024)
  • FIGURE 70 LUYE PHARMA GROUP: COMPANY SNAPSHOT (2023)
  • FIGURE 71 COMPANY SNAPSHOT: LAVIPHARM (2024)